09 Apr 2019 --- Carbiotix, a therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the health boosting potential of the gut microbiome, has closed its latest funding round. The Sweden-based company now plans to ramp up its therapeutics development activities to address a wide range of rare and leading metabolic and chronic conditions by “optimizing each person’s microbiome metabolic profile.” The company will also partner with leading pharmaceutical companies to boost its pursuance of rare disease therapeutics, according to Carbiotix CEO, Kristofer Cook.